Ophthotech, Novartis join for wet AMD treatment
New York—Ophthotech Corp. has entered into an ex-U.S. licensing and commercialization agreement with Novartis Pharmaceuticals that will focus on the treatment of wet age-related macular degeneration (AMD).
Under the agreement, Ophthotech grants Novartis exclusive rights to commercialize its lead product candidate, Fovista, in markets outside the United States, while Ophthotech retains sole rights to commercialize its drug in the United States.
Potential payments to Ophthotech under the agreement could total more than $1 billion in upfront and milestone payments, not including future royalties, according to the company.
Ophthotech will continue to lead the global phase III wet AMD pivotal clinical program of the drug, which is expected to have initial, top-line data available in 2016.
MORE ARTICLES IN THIS ISSUE
Value-based medicine analyses have indicated that glaucoma therapy has great patient benefits because it preserves their vision—which positively impacts their quality-of-life (QOL)—and it is cost effective with a high return on investment, according to Gary Brown, MD.
Allergan has received a strong outpour of support from its physician customers, their nurses, and office staff members, as well as from patient advocacy groups and medical associations following the company’s rejection of Valeant Pharmaceuticals International’s unsolicited acquisition proposal.
The FDA has granted AbbVie’s adalimumab (Humira) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.